Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term CLINICAL-TRIALS. Found 11 abstracts

Bilusic M, Wong YN. Anti-angiogenesis in prostate cancer: knocked down but not out. Asian journal of andrology. 2014 May;16(3):372-7.   PMCID: PMC4023362
de Bono JS, Piulats JM, Pandha HS, Petrylak DP, Saad F, Aparicio LM, Sandhu SK, Fong P, Gillessen S, Hudes GR, Wang T, Scranton J, Pollak MN. Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 2014 Apr;20(7):1925-34.   PMCID: No NIH funds
Gao WZ, Ma GX, Tan Y, Fang C, Weaver J, Jin M, Lai P, Godwin AK. Culturally Appropriate Education Intervention on Biospecimen Research Participation among Chinese Americans. Cancer Epidemiology Biomarkers & Prevention. 2014 Mar;23(3):383-91.   PMCID: PMC 3955025
Simon MA, de la Riva EE, Bergan R, Norbeck C, McKoy JM, Kulesza P, Dong XQ, Schink J, Fleisher L. Improving Diversity in Cancer Research Trials: The Story of the Cancer Disparities Research Network. Journal of Cancer Education. 2014 Jun;29(2):366-74.   PMCID: PMC4029870
Beer TM, Higano CS, Saleh M, Dreicer R, Hudes G, Picus J, Rarick M, Fehrenbacher L, Hannah AL. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Investigational New Drugs. 2007 Dec;25(6):565-70.
Bukowski RM, Ozols RF, Markman M. The management of recurrent ovarian cancer. Seminars in Oncology. 2007 Apr;34(2):S1-S15.
Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. Journal of Clinical Oncology. 2007 Apr;25(12):1539-44.
Janz NK, Mujahid M, Chung LK, Lantz PM, Hawley ST, Morrow M, Schwartz K, Katz SJ. Symptom experience and quality of life of women following breast cancer treatment. Journal of Womens Health. 2007 Nov;16(9):1348-61.
Posadas EM, Liel MS, Kwitkowski V, Minasian L, Godwin AK, Hussain MM, Espina V, Wood BJ, Steinberg SM, Kohn EC. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer. 2007 Apr;109(7):1323-30.
Trotti A, Pajak TF, Gwede CK, Paulus R, Cooper J, Forastiere A, Ridge JA, Watkins-Bruner D, Garden AS, Ang KK, Curran W. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncology. 2007 Jul;8(7):613-24.
Konski A, Watkins-Bruner D. The RTOG Outcomes Model: economic end points and measures. Expert Opinion on Pharmacotherapy. 2004 Mar;5(3):513-9.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term CLINICAL-TRIALS

CLINICAL-TRIALS PHASE-II TRIAL Oncology RANDOMIZED-TRIAL RADIOTHERAPY ENDOTHELIAL GROWTH-FACTOR PROGRAM DOUBLE-BLIND CARCINOMA clinical trials CHEMOTHERAPY prostate cancer CELL LUNG-CANCER BMS-247550 IGF-IR TOXICITY COSTS PREDNISONE GYNECOLOGIC-ONCOLOGY-GROUP SOLID TUMORS 1ST-LINE TREATMENT Environmental & Occupational Health Public RECEPTOR TYROSINE KINASE Occupational Health PLUS FLUOROURACIL IRINOTECAN HEALTH EUROPEAN-ORGANIZATION BODY-IMAGE underrepresented populations ADVANCED HEAD PROGRESSION-FREE SURVIVAL REFRACTORY OVARIAN Cancer research SCIENCE TYROSINE KINASE angiogenesis BREAST-CANCER COMPLETE RESPONSE COMMUNITY EPIDERMAL-GROWTH-FACTOR PRIMARY PERITONEAL PHASE-II OPEN-LABEL DESOXYEPOTHILONE-B Urology & Nephrology Biobanking gefitinib PREVENTION ONCOLOGY GROUP RTOG ADVANCED SOLID TUMORS Scientific Disciplines Education IN-VIVO Clinical trials HUMAN TUMOR XENOGRAFTS IMPACT KeyWords Plus: proteomics INSULIN TRIAL IMMUNOHISTOCHEMICAL EXPRESSION PROSTATE-CANCER GROUP RTOG DOSE-ESCALATION NECK-CANCER MALIGNANT GLIOMA DISPARITIES SQUAMOUS-CELL CARCINOMAS INCREASED SURVIVAL EGF RECEPTOR GROWTH-FACTOR RECEPTOR NEOPLASM Minority and ovarian cancer MEDICINE docetaxel epidermal growth factor receptor PROTEIN MICROARRAYS PARTICIPATION RESTORE ATTENTION ANTIBODY PROTOCOL ALPHA-FOLATE RECEPTOR HOT FLASHES SURVIVAL protein array PLUS PREDNISONE INHIBITOR CANCER economic analysis ADJUVANT CHEMOTHERAPY Environmental & Public HORMONAL-THERAPY YOUNGER WOMEN POSTMENOPAUSAL WOMEN MITOXANTRONE PLUS PREDNISONE SURVIVORS SAFETY ADJUSTED SURVIVAL ANALYSIS THERAPY Andrology
Last updated on Thursday, April 02, 2020